United States Patent 9,399,014: Ozenoxacin Cream Claims, Scope, Expiration and Generic Entry Risk

US Patent No. 9,399,014 protects a narrowly defined stable topical cream containing ozenoxacin and a specified multi-component vehicle. The patent is directed to formulation architecture rather than ozenoxacin as a molecule. Its principal commercial relevance is Xepi, a 1% ozenoxacin cream approved by the FDA for impetigo caused by susceptible strains of Staphylococcus aureus or Streptococcus pyogenes.[1,2]

The patent’s enforceable scope depends on the simultaneous presence of ozenoxacin, defined concentration ranges, specific emulsifier and surfactant classes, 2-octyldodecanol, low-melting wax, water-dispersible components, and a non-formaldehyde-donating preservative. Omitting or moving outside a required limitation can create a non-infringement position, although the doctrine of equivalents may remain relevant.

What does US Patent 9,399,014 protect?

US 9,399,014 claims a method of treating bacterial skin and skin-structure infections by administering a stable topical cream composition. Claim 1 requires all of the following:

Claim element	Required scope
Active ingredient	Ozenoxacin at 0.2% to 5% by weight
Emulsifier	15% to 25% of one or more listed emulsifiers
Surfactant	10% to 20% of one or more listed surfactants
Oil component	5% to 15% 2-octyldodecanol
Low-melting wax	1% to 10% fatty alcohols containing 8 to 30 carbon atoms
Water	Quantity sufficient to complete 100% by weight
Water-dispersible component	10% to 20% of one or more listed solvents or dispersible materials
Preservative	0.01% to 1% of one or more non-formaldehyde-donating preservatives
Therapeutic use	Treatment of skin and skin-structure bacterial infections caused by S. aureus or S. pyogenes

Claim 2 narrows claim 1 to impetigo. It does not claim every ozenoxacin formulation or every topical treatment involving ozenoxacin.

The claims are composition-dependent method claims. A party generally must practice both the administration step and the claimed formulation limitations to face direct infringement under the literal claim language. A product manufacturer can nevertheless face inducement or contributory-infringement theories if it supplies a formulation with instructions or foreseeable uses that satisfy the patented treatment method.

How narrow is the formulation claim?

The claim is materially narrower than a conventional active-ingredient patent. It requires a particular formulation platform with multiple quantitative limitations.

The most commercially important limitations are:

Ozenoxacin concentration of 0.2% to 5%.
2-octyldodecanol at 5% to 15%.
Emulsifier content of 15% to 25%.
Surfactant content of 10% to 20%.
Water-dispersible component content of 10% to 20%.
A non-formaldehyde-donating preservative.
A stable cream dosage form.

A competing formulation outside any one required range may avoid literal infringement. For example, a cream containing 1% ozenoxacin but 4% 2-octyldodecanol would fall outside the express oil-component range. A formulation using a different oil instead of 2-octyldodecanol also presents a potential design-around, subject to claim-construction and equivalents analysis.

The Markush language broadens the claim within each category. The listed alternatives include specific emulsifiers, surfactants, water-dispersible components and fatty alcohols. The claim also allows mixtures. It does not, however, expressly cover every pharmaceutically acceptable excipient.

What is the scope of the ozenoxacin percentage limitation?

The claimed ozenoxacin range is 0.2% to 5% by weight. A 1% product, such as the FDA-approved Xepi cream, falls inside that range.[1]

The range is likely to be interpreted according to ordinary pharmaceutical formulation principles, with percentages calculated against total composition weight. A product at exactly 0.2% or exactly 5% would generally be within the literal range unless another claim-construction issue applies. A product below 0.2% or above 5% would require an equivalents analysis rather than literal infringement.

The concentration limitation does not by itself protect ozenoxacin cream. Every other required formulation limitation remains relevant.

What formulations are protected by US 9,399,014?

The protected formulations must contain the following formulation structure:

A relatively high emulsifier fraction.
A separate surfactant fraction.
2-octyldodecanol as the oil phase.
One or more C8-C30 fatty alcohol waxes.
Water.
A water-dispersible solvent or solubilizing component.
A non-formaldehyde-donating preservative.

The claim identifies numerous alternatives for the emulsifier and surfactant categories. Examples include ethylene glycol monostearate, hydrogenated lecithin, soy lecithin, egg phosphatides, sucrose fatty acid esters, polyglycerol fatty-acid esters, polyethylene glycol 400, propylene glycol, ethoxydiglycol and dimethyl isosorbide.

This structure appears directed to physical stability, dispersion and topical performance. The patent does not claim stability through a single analytical threshold in the quoted claims. Instead, it defines the formulation ingredients and concentration windows.

What does claim 2 add for impetigo?

Claim 2 limits the treatment to impetigo. It is narrower than claim 1 but commercially significant because the FDA-approved indication for Xepi is impetigo due to susceptible S. aureus or S. pyogenes.[1]

Claim 2 may be relevant in an ANDA or labeling dispute. A generic applicant seeking approval for the same impetigo indication would face a method-of-use issue if the patent is listed in the Orange Book and remains enforceable. A section viii statement could be available only if the applicant omits the patented indication and the FDA-approved product has a separable non-patented use.

What is the FDA and Orange Book status of ozenoxacin?

The FDA approved Xepi, ozenoxacin 1% cream, in December 2017 for topical treatment of impetigo caused by susceptible strains of S. aureus or S. pyogenes in patients two months of age and older.[1]

Ozenoxacin is a small-molecule quinolone antibiotic. It is not a biologic, so biosimilar provisions under the Public Health Service Act do not apply. A competing manufacturer would normally use the abbreviated new drug application pathway, not a biosimilar application.

US 9,399,014 is associated with the Xepi formulation patent estate and has been identified in public pharmaceutical patent databases as a key US patent covering the product’s stable topical formulation.[2,3] Orange Book listing and current patent certification positions should be assessed against the FDA’s current Approved Drug Products with Therapeutic Equivalence Evaluations database because listing status can change through patent delisting, expiration, or regulatory updates.[3]

When does US 9,399,014 lose exclusivity?

The patent issued on July 26, 2016.[2] Public patent records identify an expiration date in the 2030 period, commonly reported as April 23, 2030 for this US patent family.[2,4]

Event	Date
US patent grant	July 26, 2016
Reported patent expiration	April 23, 2030
FDA Xepi approval	December 2017
FDA product exclusivity	New chemical entity exclusivity initially ran for five years from approval, subject to statutory adjustments

Patent expiry and regulatory exclusivity are separate. The five-year new chemical entity period did not extend to 2030. The commercial barrier after regulatory exclusivity depends primarily on the remaining patent estate, Orange Book listings, ANDA certifications, litigation and any settlement terms.

A patent-term-extension analysis should distinguish ordinary patent expiration from any patent-term adjustment, patent-term extension, terminal disclaimer or pediatric exclusivity. The reported 2030 date is the operative public expiry date associated with US 9,399,014.[2,4]

How many patents cover Xepi and ozenoxacin?

US 9,399,014 is the principal patent addressed here, but it should not be treated as the entire ozenoxacin estate. Commercial protection can include separate patent families directed to:

Ozenoxacin composition of matter.
Topical formulations.
Stable emulsions or creams.
Methods of treating impetigo.
Other bacterial skin infections.
Manufacturing and formulation processes.
Foreign counterparts and national-phase applications.

The relevant question for generic entry is not the raw number of patents. It is whether any unexpired, listed patent reads on the proposed product or labeling. A generic applicant must evaluate each Orange Book-listed patent and may submit a Paragraph III certification, Paragraph IV certification or section viii statement, depending on the patent and proposed labeling.

What Paragraph IV risks exist?

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable or will not be infringed by the proposed ANDA product. For US 9,399,014, the strongest generic arguments would likely focus on claim construction and formulation differences.

Potential design-around or invalidity positions include:

Replacing 2-octyldodecanol with another emollient or oil.
Reducing or increasing the emulsifier level outside 15% to 25%.
Using a surfactant system outside the 10% to 20% range.
Using a preservative that falls outside the claimed category.
Demonstrating that the formulation is not a cream or is not stable under the patent’s proper construction.
Challenging written description, enablement or obviousness based on prior art formulations.

The patent holder would likely emphasize the combination of narrow ingredient classes and numerical ranges. A challenger would need to address whether the claimed combination was predictable from prior topical quinolone and emulsion technology, not merely whether each ingredient was individually known.

Which companies are challenging ozenoxacin patent protection?

Publicly available records associated with US 9,399,014 do not establish a major reported US Paragraph IV trial or a publicly disclosed settlement involving a named ANDA challenger. The absence of a reported case does not eliminate future challenge risk. Generic companies may submit certifications without immediate public litigation, or a dispute may remain confidential until an ANDA notice triggers a patent-holder response.

The commercial sponsor associated with Xepi is Ferrer International and related Ferrer entities. A generic applicant would face the Orange Book patent and any other listed Xepi patents separately.[1-3]

How strong is the patent estate for generic-entry analysis?

US 9,399,014 has moderate-to-strong formulation protection but limited breadth outside its specified composition.

Strength factor	Assessment
Active ingredient coverage	Narrow; the claim does not cover all ozenoxacin products
Formulation specificity	Strong; multiple mandatory ingredient classes and ranges
Design-around potential	Meaningful, particularly through oil, emulsifier and surfactant changes
Method-of-use coverage	Relevant to impetigo and specified bacterial infections
Small-molecule generic exposure	High after regulatory exclusivity, subject to patent status
Biosimilar exposure	Not applicable
Manufacturing barrier	Potentially meaningful if stability depends on the claimed excipient architecture
Litigation leverage	Highest where the proposed generic closely copies the Xepi formulation

The claim’s commercial value is greatest against a copycat cream. It is less effective against a genuinely different ozenoxacin vehicle, a different dosage form or a product marketed without the patented indication.

What litigation and settlement issues affect entry?

A Paragraph IV notice can trigger a patent-infringement action under 35 U.S.C. §271(e)(2). A timely action can delay FDA approval for up to 30 months, subject to statutory exceptions and court action.[5]

A settlement could establish a licensed entry date before patent expiry, an authorized-generic arrangement, supply terms or restrictions on the generic label. No publicly reported settlement tied specifically to US 9,399,014 is established in the cited records.

The principal litigation issues would likely include infringement of the full formulation combination, claim construction for “stable topical cream composition,” numerical range interpretation, obviousness, and whether the accused product’s instructions induce the claimed treatment method.

How does ozenoxacin compare with competing topical antibiotics?

Ozenoxacin differs from mupirocin and retapamulin in both active ingredient and patent position. Mupirocin has long-established generic competition and a mature topical-antibiotic market. Retapamulin also has a separate product and patent history. Ozenoxacin’s commercial differentiation is tied to a non-fluorinated topical quinolone with an FDA-approved impetigo indication and a formulation patent estate.[1]

Product	Active ingredient	Main US use	Generic/biosimilar pathway
Xepi	Ozenoxacin 1% cream	Impetigo	ANDA
Bactroban	Mupirocin	Impetigo and other skin infections	ANDA
Altabax	Retapamulin	Impetigo	ANDA
Biologic topical products	Varies	Product-specific	Biosimilar pathway only if biologic

What generic launch scenarios exist?

Three launch scenarios are commercially plausible:

Post-expiry launch: A generic launches after all relevant listed patents expire or are otherwise resolved.
Paragraph IV launch: A generic challenges US 9,399,014 and launches after litigation victory, settlement, or failure to obtain timely injunctive relief.
Design-around launch: A generic uses a formulation outside the claim and supports non-infringement through an ANDA certification and product-specific analysis.

The most credible design-around route is a materially different vehicle. A generic that retains 2-octyldodecanol, the same concentration ranges and the same excipient architecture would present higher infringement risk.

What geographic coverage does the patent have?

US 9,399,014 provides protection only in the United States. Foreign counterparts may protect corresponding formulations in Europe and other jurisdictions, but a US patent cannot block manufacture, sale or use solely outside the United States unless another jurisdiction’s patent applies.

For global licensing or supply transactions, counsel must map the patent family by country, legal status, patent-term adjustment, supplementary protection certificate status and local regulatory linkage. The United States remains the principal market relevant to Xepi’s FDA approval and ANDA pathway.

Key Takeaways

US 9,399,014 is a formulation and treatment patent, not a broad ozenoxacin composition-of-matter patent.
Claim 1 requires every listed formulation category and its specified concentration range.
Claim 2 narrows protection to impetigo.
A 1% ozenoxacin cream falls within the claimed active-ingredient range.
The most important infringement limitations are 2-octyldodecanol, the emulsifier and surfactant ranges, the water-dispersible component range, and the non-formaldehyde-donating preservative.
The patent was granted July 26, 2016, with a publicly reported expiration date of April 23, 2030.
Ozenoxacin is a small molecule, so future competition proceeds through ANDA litigation and certification, not biosimilar litigation.
A generic using a materially different vehicle has a stronger design-around position than a product closely replicating the Xepi cream.
Patent expiry, Orange Book status, regulatory exclusivity and any other Xepi patents must be assessed together before forecasting launch.

FAQs

Can a generic use 1% ozenoxacin without infringing US 9,399,014?

Not necessarily. The 1% concentration satisfies one limitation, but infringement requires analysis of the complete formulation and the proposed method of use.

Does US 9,399,014 cover ozenoxacin gel or ointment products?

The quoted claims require a stable topical cream composition. A gel or ointment may avoid literal infringement, although the result depends on formulation characteristics and claim construction.

Is 2-octyldodecanol essential to the patent claim?

Yes. Claim 1 expressly requires 5% to 15% of the Guerbet alcohol 2-octyldodecanol as the oil component.

Can a generic omit impetigo from its label to avoid claim 2?

Potentially, but omission must be evaluated against the full FDA-approved labeling, remaining uses, induced-infringement theories and other listed patents.

Does patent expiry automatically permit immediate Xepi generic launch?

No. A launch also depends on FDA approval, Orange Book certifications, other unexpired patents, pediatric exclusivity, litigation outcomes and any settlement restrictions.

References

U.S. Food and Drug Administration. (2017). Xepi (ozenoxacin) cream, 1% prescribing information.
U.S. Patent and Trademark Office. (2016). U.S. Patent No. 9,399,014, stable topical pharmaceutical compositions comprising ozenoxacin.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
Google Patents. (2024). US9399014B2 patent record.
35 U.S.C. § 271(e)(2) and 21 U.S.C. § 355(j).

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Lnhc	XEPI	ozenoxacin	CREAM;TOPICAL	208945-001	Dec 11, 2017		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	08166933	Oct 17, 2008

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2344130	⤷ Start Trial	300884	Netherlands	⤷ Start Trial
European Patent Office	2344130	⤷ Start Trial	122017000073	Germany	⤷ Start Trial
European Patent Office	2344130	⤷ Start Trial	2017C/031	Belgium	⤷ Start Trial
European Patent Office	2344130	⤷ Start Trial	1790031-7	Sweden	⤷ Start Trial
European Patent Office	2344130	⤷ Start Trial	C201730036	Spain	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,399,014

Which drugs does patent 9,399,014 protect, and when does it expire?

Summary for Patent: 9,399,014